StreetInsider.com News Articles

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 01 Sep 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.

A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Tue, 01 Sep 2026 16:05:00 -0400

About Veracyte

Veracyte (Nasdaq: VCYT) is a global diagnostics company with a

Veracyte, Inc (VCYT) PT Lowered to $44 at Morgan Stanley

Tue, 04 Aug 2026 08:13:17 -0400

Morgan Stanley analyst Kallum Titchmarsh lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $44.00 (from $47.00) while maintaining a Equalweight rating.

Veracyte, Inc (VCYT) PT Lowered to $55 at Stephens

Tue, 04 Aug 2026 07:29:43 -0400

Stephens analyst Mason Carrico lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $55.00 (from $68.00) while maintaining a Overweight rating.

Veracyte, Inc (VCYT) PT Lowered to $54 at Piper Sandler

Tue, 04 Aug 2026 06:55:38 -0400

Piper Sandler analyst David Westenberg lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $54.00 (from $66.00) while maintaining a Overweight rating.

Veracyte, Inc (VCYT) PT Lowered to $50 at Canaccord

Mon, 03 Aug 2026 05:50:48 -0400

Canaccord analyst Kyle Mikson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $50.00 (from $60.00) while maintaining a Hold rating.

The analyst comments "We reiterate our HOLD rating on Veracyte (VCYT) shares and decrease our price target to $50 from $60. Our price target decrease is driven by lower revenue estimates in the out years of our 10-year DCF model. After the market close on Thursday, July 30, the company reported 2Q26 results that were ahead of our estimates and FactSet consensus. VCYT's performance was partially driven by 14% y/y testing volume expansion (particularly Decipher [+17% y/y; albeit below

Veracyte, Inc (VCYT) PT Lowered to $50 at Canaccord

Mon, 03 Aug 2026 05:50:48 -0400

Canaccord analyst Kyle Mikson lowered the price target on Veracyte, Inc (NASDAQ: VCYT) to $50.00 (from $60.00) while maintaining a Hold rating.

Form 10-Q VERACYTE, INC. For: Jun 30

Fri, 31 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260731/26850855.html

Form 10-Q VERACYTE, INC. For: Jun 30

Fri, 31 Jul 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260731/26850855.html

Veracyte, Inc (VCYT) PT Raised to $66 at Freedom Capital

Fri, 31 Jul 2026 06:21:44 -0400

Freedom Capital analyst Keith Hinton raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $66.00 (from $54.00) while maintaining a Buy rating.

The analyst comments "VCYT reported 2Q26 earnings yesterday after market close. While Decipher volume was a modest disappointment, 2Q results were otherwise strong with revenue +2-4% above our & Street estimates and EBITDA +18-19% above, continuing VCYT’s near-perfect track record of beat-and-raise quarters since management joined in 2021. Revenue guidance came up by ~1% and EBITDA margin guidance was unchanged; changes to our 2026 and 2027 estimates are minimal. We view commentary on early feedback for Prosigna (and

Veracyte, Inc (VCYT) PT Raised to $66 at Freedom Capital

Fri, 31 Jul 2026 06:21:44 -0400

Freedom Capital analyst Keith Hinton raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $66.00 (from $54.00) while maintaining a Buy rating.

Veracyte, Inc (VCYT) PT Raised to $69 at Needham

Fri, 31 Jul 2026 05:08:52 -0400

Needham analyst Mike Matson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $69.00 (from $57.00) while maintaining a Buy rating.

The analyst comments "VCYT's 2Q26 revenue and EPS beat consensus. Management raised 2026 revenue guidance and maintained its 2026 EBITDA margin guidance. Revenue growth slowed to 16% in 2Q26 from 22% in 1Q26, driven by strong Decipher and Afirma volumes and as VCYT faced a tough comp from NCCN guideline inclusion in early 2025. Non-GAAP gross margin was up 340 bps Y/Y and non-GAAP operating margin was up 320 bps Y/Y. Management believes that VCYT can deliver durable double-digit

Veracyte, Inc (VCYT) PT Raised to $69 at Needham

Fri, 31 Jul 2026 05:08:52 -0400

Needham analyst Mike Matson raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $69.00 (from $57.00) while maintaining a Buy rating.

Veracyte (VCYT) Tops Q2 EPS by 11c; Offers Guidance

Thu, 30 Jul 2026 16:30:18 -0400

Veracyte (NASDAQ: VCYT) reported Q2 EPS of $0.54, $0.11 better than the analyst estimate of $0.43. Revenue for the quarter came in at $150.32 million versus the consensus estimate of $144.56 million.

GUIDANCE:

Veracyte sees FY2026 revenue of $590-596 million, versus the consensus of $585.5 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.

Veracyte (VCYT) Tops Q2 EPS by 11c; Offers Guidance

Thu, 30 Jul 2026 16:30:18 -0400

Veracyte (NASDAQ: VCYT) reported Q2 EPS of $0.54, $0.11 better than the analyst estimate of $0.43. Revenue for the quarter came in at $150.32 million versus the consensus estimate of $144.56 million.

GUIDANCE:

Veracyte sees FY2026 revenue of $590-596 million, versus the consensus of $585.5 million.

For earnings history and earnings-related data on Veracyte (VCYT) click here.

Form 8-K VERACYTE, INC. For: Jul 30

Thu, 30 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260730/26843916.html

Form 8-K VERACYTE, INC. For: Jul 30

Thu, 30 Jul 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260730/26843916.html

Veracyte Announces Second Quarter 2026 Financial Results